This study evaluates the outcomes of patients undergoing initial therapy for multiple myeloma.
PRIMARY OBJECTIVE: I. Compare the overall survival between bortezomib, lenalidomide and dexamethasone (VRd), daratumumab, lenalidomide and dexamethasone (DRd) and daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) used as initial therapy for patients with newly diagnosed MM. OUTLINE: This is an observational study. Patients have their medical records reviewed on study.
Study Type
OBSERVATIONAL
Enrollment
50
Non-interventional study
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, United States
Overall survival
Overall survival, defined as the time from initiation of therapy to the time of death due to any cause, will be assessed by review of medical record, contacting the participant, or contacting the participant's local physician every 3 months for up to 10 years after participant starts the study.
Time frame: Every 3 months, up to 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.